Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Teva Pharmaceutical Industries Ltd (NY: TEVA)
21.19 USD  -1.07 (-4.81%)
Official Closing Price  /  Updated: 7:45 PM EDT, Oct 17, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 13,095,100
Open 21.70
Bid (Size) 21.10 (15)
Ask (Size) 21.20 (25)
Prev. Close 22.26
Today's Range 20.87 - 21.70
52wk Range 10.85 - 25.96
Shares Outstanding 1,018,482,488
Dividend Yield 5.62%
Performance
YTD
+10.88%
+10.88%
1 Month
-9.56%
-9.56%
3 Month
-9.94%
-9.94%
6 Month
+18.25%
+18.25%
1 Year
+43.76%
+43.76%
Top News
More News
Stocks To Watch: Teva Pharmaceutical Sees RS Rating Rise To 84
A Relative Strength Rating upgrade for Teva Pharmaceutical shows improving technical performance. Read More
from Investor's Business Daily
Regeneron's Drug Will Be Fifth In Asthma — But 'It Will Be The Best'
Regeneron Pharmaceuticals' potential blockbuster drug, Dupixent, has a shot at grabbing a broad approval in asthma treatment, an analyst said Thursday. Read More
from Investor's Business Daily
More News
Read More
Regeneron's Drug Will Be Fifth In Asthma — But 'It Will Be The Best'
from Investor's Business Daily
Teva Pharmaceutical Clears Key Benchmark, Hitting 80-Plus RS Rating
from Investor's Business Daily
Teva Presents 25-year Safety Data from Longest Continuous Trial of COPAXONE® (glatiramer acetate injection) for the Treatment of Relapsing Forms of Multiple Sclerosis
from Business Wire News Releases
UPDATE 1-Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva
category companyNews
from Reuters: Company News
Stocks making the biggest move premarket: NFLX, IBM, CSX, UAL, TEVA & more
category Teva Pharmaceutical Industries Ltd , Netflix Inc , Economics/Economy , and 16 more.
from CNBC.com News
Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA for CT-P10, a Proposed Rituximab Biosimilar
from Business Wire News Releases
Generic Pharma Slides Despite Bullish View On Biosimilar Efforts
from Investor's Business Daily
UPDATE 1-U.S. appeals court upholds ruling that canceled Teva Copaxone patents
category companyNews
from Reuters: Company News
U.S. appeals court upholds ruling that canceled Teva Copaxone patents
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.